MedTrace Logo

PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.

NCT00741481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2011-02-24

No results posted yet for this study

Summary

Study hypothesis : early decrease in fdg-pet measured SUV max after 1 cycle of chemotherapy can accurately predict response of chemotherapy as assessed by conventional radiology after 3 cycles of chemotherapy.

FDG-PET imaging will be done at J0 and J14 of a new line of chemotherapy treatment in metastatic colorectal cancer.

SUV max will be recorded and delta SUVmax will be compared to the results of conventional radiological evaluation after 3 courses of chemotherapy. Results will also be compared to the time to disease progression.

Conditions

  • Colorectal Cancer Metastatic
  • Early Response Evaluation
  • Fdg-PET

Interventions

PROCEDURE

FDG-PET imaging

FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Alain - Hendlisz, MD · Institut Jules Bordet, Université Libre de Bruxelles, Brussels

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741481 on ClinicalTrials.gov